NASDAQ:ATAI 18 October 2025

Atai Life Sciences shares surged 18% to close near $6.45 on Oct. 17, 2025, after the FDA granted Breakthrough Therapy status to its experimental depression nasal spray BPL-003. The company raised $130 million in a public offering at $5.48 per share. Analysts issued strong Buy ratings with targets up to $15. ARK Invest disclosed buying about 250,000 shares.

ATAI Life Sciences shares jumped 17.7% Friday to $6.45 after the FDA granted Breakthrough Therapy Designation to its depression drug BPL-003 and the company announced a $130 million public offering. Jefferies and H.C. Wainwright raised price targets, citing the FDA news. The stock is up over 300% year-to-date. After-hours trading pushed shares to $6.86.